Benefit-risk assessment of brensocatib for treatment of non-cystic fibrosis bronchiectasis.

Authors :: Chalmers JD
Metersky ML
Feliciano J
Fernandez C
Teper A
Maes A
Hassan M
Chatterjee A
Source :: ERJ open research [ERJ Open Res] 2023 May 02; Vol. 9 (3). Date of Electronic Publication: 2023 May 02 (Print Publication: 2023).
Publication Year :: 2023
Abstract: Brensocatib is a novel anti-inflammatory therapy in development for bronchiectasis treatment. Phase 2 WILLOW trial data demonstrate a low number needed to treat and negative number needed to harm, suggesting a favourable benefit-risk profile. https://bit.ly/3SbisW3.<br />Competing Interests: Conflict of interest: J.D. Chalmers has received grants and personal fees from AstraZeneca, Boehringer Ingelheim, GSK, Zambon and Insmed Incorporated; a grant from Gilead; and personal fees from Novartis and Chiesi within the past 24 months. He is an associate editor of this journal. Conflict of interest: M.L. Metersky has received consulting fees from Insmed Incorporated, Boehringer Ingelheim, California Institute for Biomedical Research and Zambon; and his institution has received clinical trial support from Insmed Incorporated. Conflict of interest: J. Feliciano, C. Fernandez, A. Teper, A. Maes, M. Hassan and A. Chatterjee are employed by Insmed Incorporated.<br /> (Copyright ©The authors 2023.)

Full Text Access

Tools